SG
MRNA icon

Sankala Group’s Moderna MRNA Stock Holding History

Sankala Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$427K Buy
8,318
+174
+2% +$8.12K 0.35% 66
2025
Q4 		$436K Buy
+8,144
New +$221K 0.35% 67

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sankala Group's MRNA Position: Q1 2026 in Review

Sankala Group increased its Moderna (MRNA) stake by 2.1% in Q1 2026, buying an estimated $8.12K and bringing the position to 8,318 shares worth $427K. The position accounts for 0.35% of the portfolio, ranked #66.

Sankala Group first reported a position in MRNA in Q4 2025 and has held it in 2 quarters since. The position peaked at $436K in Q4 2025. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Sankala Group held 8,318 shares of Moderna worth $427K as of Q1 2026.
  • Sankala Group bought 174 Moderna shares in Q1 2026, an estimated $8.12K.
  • Moderna made up 0.35% of Sankala Group's portfolio in Q1 2026, its #66 holding.
  • Sankala Group first reported a position in Moderna in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's Moderna position peaked at $436K in Q4 2025.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.